Syna Therapeutics

Executive Summary

Syna Therapeutics, a Spanish biopharmaceutical joint venture formed in 2019 between Reig Jofre and LeanBio, is focused on developing, manufacturing, and commercializing biosimilar medicines and innovative molecules. The company leverages a fully integrated model spanning R&D through large-scale manufacturing, positioning itself to address the growing global demand for affordable biologic treatments. With operations based in Barcelona, Syna Therapeutics aims to capitalize on the expanding biosimilar market, estimated to reach over $100 billion by 2030, driven by patent expirations of key biologics and cost-containment pressures on healthcare systems. The partnership combines Reig Jofre's established pharmaceutical manufacturing and commercialization expertise with LeanBio's biosimilar development capabilities, creating a vertically integrated player in the European biosimilar landscape. While the company remains in a pre-commercial stage and has not yet disclosed specific pipeline candidates or regulatory filings, its strategic focus on high-value biologic targets and local manufacturing infrastructure could enable it to compete effectively in both domestic and international markets.

Upcoming Catalysts (preview)

• Q2 2026Completion of large-scale manufacturing facility qualification75% success
• Q4 2026First biosimilar candidate enters clinical trials50% success
• TBDLicensing or partnership agreement for ex-Spain commercialization40% success